Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558–Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population

James P. Apland, Vassiliki Aroniadou-Anderjaska, Taiza H. Figueiredo, Volodymyr I. Pidoplichko, Katia Rossetti, and Maria F. M. Braga

Neuroscience Branch, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland (J.P.A.); and Departments of Anatomy, Physiology, and Genetics (V.A.-A., T.H.F., V.I.P., K.R., M.F.M.B.) and Psychiatry (V.A.-A., M.F.M.B.), F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland

Received October 26, 2017; accepted February 8, 2018

ABSTRACT

The currently Food and Drug Administration–approved anticonvulsant for the treatment of status epilepticus (SE) induced by nerve agents is the benzodiazepine diazepam; however, diazepam does not appear to offer neuroprotective benefits. This is of particular concern with respect to the protection of children because, in the developing brain, synaptic transmission mediated via GABA_A receptors, the target of diazepam, is weak. In the present study, we exposed 21-day-old male rats alone, terminated SE; LY293558 (an AMPA/GluK1 receptor antagonist; 15 mg/kg), caramiphen (CRM, an antimuscarinic with NMDA receptor–antagonistic properties; 50 mg/kg), and LY293558 (15 mg/kg) + CRM (50 mg/kg), administered 1 hour after exposure. Diazepam, LY293558, and LY293558 + CRM, but not CRM alone, terminated SE; LY293558 + CRM treatment acted significantly faster and produced a survival rate greater than 85%. Thirty days after soman exposure, neurodegeneration in limbic regions was most severe in the CRM–treated group, minimal to severe—depending on the region—in the diazepam group, absent to moderate in the LY293558–treated group, and totally absent in the LY293558 + CRM group. Amygdala and hippocampal atrophy, a severe reduction in spontaneous inhibitory activity in the basolateral amygdala, and increased anxiety-like behavior in the open-field and acoustic startle response tests were present in the diazepam and CRM groups, whereas the LY293558 and LY293558 + CRM groups did not differ from controls. The combined administration of LY293558 and CRM, by blocking mainly AMPA, GluK1, and NMDA receptors, is a very effective anticonvulsant and neuroprotective therapy against soman in young rats.

Introduction

Acute exposure to nerve agents can cause brain damage or death. The primary action of these organophosphorus neurotoxins is inhibition of acetylcholinesterase (Sirin et al., 2012). Death may ensue because of the peripheral cholinergic crisis that follows acetylcholinesterase inhibition and/or the prolonged seizures and status epilepticus (SE), which are initiated by excessive accumulation of acetylcholine in neuronal synapses in the brain and overstimulation of cholinergic receptors. If death is prevented by pharmacologic intervention, brain damage may still occur, caused primarily by the SE (Shih et al., 2003; Frager et al., 2013) but also via mechanisms independent of seizures (Yokoyama, 2007; Pereira et al., 2014). The neurologic, cognitive, and/or emotional deficits that follow nerve agent–induced brain damage are long-lasting, as we know from animal studies (Aroniadou-Anderjaska et al., 2016), but also from studies in humans after the terrorist attacks in Matsumoto in 1994 and Tokyo in 1995 (Murata et al., 1997; Sekijima et al., 1997; Ohtani et al., 1995; Murata et al., 1997; Sekijima et al., 1997; Ohtani et al., 2004; Yanagisawa et al., 2006). Unfortunately, devastating nerve agent attacks occur nowadays as well, as in Syria (Dolgin, 2013), and the long-term health consequences on the surviving victims, many of which are children, may become known only after these conflicts end.

Seizures, after acute nerve agent exposure, are triggered by muscarinic receptor hyperstimulation owing to elevated acetylcholine, and muscarinic receptor antagonists are effective...
in halting nerve agent–induced seizures if they are administered shortly after exposure (Lallemand et al., 1998; Shih and McDonough, 1999; Skovira et al., 2010). Muscarinic receptor hyperstimulation is followed by glutamatergic hyperactivity, which intensifies and sustains SE (McDonough and Shih, 1997) and is largely responsible for excitotoxic neuronal damage (Shih et al., 2003; Deshpande et al., 2014a). Excessive glutamatergic activity can be counteracted by blocking certain types of glutamate receptors or by enhancing GABAA receptor–mediated inhibition. Accordingly, benzodiazepines, which are positive allosteric modulators of GABAA receptors, are the first-line treatment of SE, regardless of its cause (Cherian and Thomas, 2009; Trinka and Kalviainen, 2017), and diazepam (a benzodiazepine) is the currently Food and Drug Administration–approved anticonvulsant for treating nerve agent–induced seizures. Benzodiazepines, however, lose their efficacy as the latency of administration from the onset of SE increases (Walton and Treiman, 1991; Jones et al., 2002; Goodkin et al., 2003; Cherian and Thomas, 2009; McDonough et al., 2010; Todorovic et al., 2012; Niquet et al., 2016; Trinka and Kalviainen, 2017); anticonvulsant efficacy at delayed post-SE-onset time points is necessary in a scenario of mass exposure to nerve agents when medical assistance may not be available immediately. Furthermore, the neuroprotective efficacy of benzodiazepines is limited (de Araujo Furtado et al., 2010; Langston et al., 2012; Apland et al., 2014). The drawbacks of the benzodiazepines in terminating seizures and protecting from brain damage may relate to the internalization and downregulation of GABAA receptors that occur as SE progresses (Goodkin et al., 2005; Naylor et al., 2005; Deeb et al., 2012). In contrast, glutamate receptors are upregulated during prolonged seizure activity (Naylor et al., 2013; Rajasekaran et al., 2013; Wasterlain et al., 2013). Therefore, antagonizing directly the hyperactivity of the glutamatergic system rather than attempting to enhance GABAergic activity may be a more efficacious approach for terminating nerve agent–induced seizures and protecting from brain damage.

We have previously demonstrated that LY293558 ((3S, 4aR, 6R, 8aR)-6-[(1)(2)-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid; Bleakman et al., 1996), an antagonist of both AMPA receptors and the kainate receptors that contain the GluK1 subunit (formerly known as GluK5 subunit; see Jane et al., 2009), stops seizures induced by soman and significantly protects against neuronal damage, even if it is administered at 1 hour or longer after the exposure in either adult (Figueiredo et al., 2011b) or immature (P21) rats (Miller et al., 2015). In adult rats, LY293558 is far superior to DZP in protecting against soman-induced brain damage (Figueiredo et al., 2011b; Apland et al., 2013, 2014; Aroniadou-Anderjaska et al., 2016). Comparisons of the efficacies of these two anticonvulsants in protecting the developing brain have not been made so far; the first aim of the present study was to provide these data. The second aim was to determine whether combining LY293558 with an antagonist of NMDA receptors can offer greater neuroprotection against soman-induced damage than that of LY293558 alone. Therefore, we tested the combination of LY293558 with caripiphen (CRM), an M1 muscarinic receptor antagonist (Hudkins et al., 1993) with NMDA receptor antagonistic properties (Raveh et al., 1999; Figueiredo et al., 2011a), which has been shown previously to offer protection against nerve agent-induced seizures (Raveh et al., 2003, 2008; Figueiredo et al., 2011a) and neuropathology (Figueiredo et al., 2011a) in adult rats. Antagonism of NMDA receptors is particularly relevant to neuroprotection—as calcium influx via NMDA receptors plays a primary role in excitotoxic neuronal death (Portera-Cailliau et al., 1997; Liu et al., 2007; Fujikawa, 2015)—and it may be even more crucial in young subjects, when NMDA receptor activity is exceptionally high (Johnston, 1994).

Materials and Methods

Animals. Sprague-Dawley male rats (Charles River Laboratories, Wilmington, MA), 21 days old (P21; 50–60 g body weight at the time of soman exposure) were housed in an environmentally controlled room (20–23°C, 12-hour light/12-hour dark cycle, lights on 06:00 AM) in groups of five with a surrogate mother. Food and water were available ad libitum. The rats were weaned on the day of the experiments. Experiments were conducted according to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council) and were approved by the Institutional Animal Care and Use Committees of the U.S. Army Medical Research Institute of Chemical Defense and the Uniformed Services University of the Health Sciences. We used P21 rats because we are interested in the applicability of the findings to the pediatric population. P21 rats would correspond to about a 6-month-old human if we use the conversion factor for the early developmental phase (Andrello et al., 2012; Sengupta, 2013). Because the developmental stage of the brain in the two species must be considered (Andersen, 2003), and synaptogenesis—which is a basic parameter of brain development—is completed within the first 3 weeks of life in rats and in about 3.5 years in humans (Pressler and Auvin, 2013), a P21 rat would correspond to a human close to 4 years of age.

Drug Administration and Seizure Assessment. Soman (pina- colyl methylphosphonofluoridate; obtained from the U.S. Army Edge- wood Chemical Biologic Center, Aberdeen Proving Ground, MD) was diluted in cold saline and administered to P21 rats via a single subcutaneous injection at the dose of 74.4 µg/kg, which corresponds to 1.2 × LD50 (Miller et al., 2015). To minimize the peripheral effects of soman, the rats were injected i.m. with 0.5 mg/kg atropine sulfate (Vedco Inc., St. Joseph, MO) and 125 mg/kg 1-(2-hydroxyiminomethylpyridinium)-3-(4-carboxamolpyridinium)-2-oxaparane dichloride (HI-6, i.p.; Starks Associates, Buffalo, NY) within 1 minute after soman injection. The soman-exposed rats were randomly divided into four treatment groups, which, at 60 minutes after soman exposure, received 15 mg/kg LY293558 (provided by Raptor Pharmaceutical Corp., Novato, CA), 10 mg/kg DZP (Hospira Inc., Lake Forest, IL), 50 mg/kg CRM edisylate (Sigma-Aldrich, St Louis, MO), or the combination of 15 mg/kg LY293558 and 50 mg/kg CRM. All anticonvulsants were injected intramuscularly because this would be the administration route in convulsing humans. Control animals received saline instead of soman and were not injected with any anticonvulsant. Seizures were monitored behaviorally and classified according to a minimally modified version of the Racine scale (Racine, 1972), as we have previously described (Figueiredo et al., 2011b): stage 0, no behavioral response; stage 1, behavioral arrest; stage 2, oral/facial movements, chewing, head nodding; stage 3, unilateral/bilateral forelimb clonus without rearing, Straub tail, extended body posture; stage 4, bilateral forelimb clonus plus rearing; stage 5, rearing and falling; and stage 6, full tonic seizures. After soman injection, rats that went on to develop stage 3 seizures or above were considered to have SE.

Brain and Tissue Processing. Neuropathological analysis was performed in the amygdala, piriform cortex, and CA1, CA3 and hilar areas of the ventral hippocampus 30 days after soman exposure; we study neurodegeneration in the ventral hippocampus because we have seen previously that it displays significantly more severe neurodegeneration after soman exposure than the dorsal hippocampus.
Thirty days after soman administration, rats were deeply anesthetized with pentobarbital (75–100 mg/kg, i.p.) and transcardially perfused with phosphate-buffered saline (PBS, 100 ml), followed by 4% paraformaldehyde (200 ml). The brains were removed and postfixed overnight at 4°C, then transferred to a solution of 30% sucrose in PBS for 72 hours, and frozen with dry ice before storage at −80°C until sectioning. A 1-in-5 series of sections from the rostral extent of the amygdala to the caudal extent of the entorhinal cortex was cut at 40 μm on a sliding microtome. One series of sections was mounted on slides (Superfrost Plus; Daigster, Vernon Hills, IL) in PBS for Nissl staining with cresyl violet. Adjacent series of sections were mounted on slides for Fluoro-Jade C (FJC) staining.

Volumetric Analysis. Volumetric analysis was performed 30 days after soman exposure. Nissl-stained sections containing the amygdala (sections were 200 μm apart) or the hippocampus (sections were 400 μm apart) were used to estimate stereologically the volume of these structures based on the previously described Cavalieri principle (Gundersen et al., 1989). Sections were viewed with a Zeiss Axioplan 2ie fluorescence microscope (Oberkochen, Germany) equipped with a motorized stage and interfaced with a computer running Stereo Investigator 9.0. The amygdala and the hippocampus were identified on slide-mounted sections under a 2.5× objective, based on the atlas of Paxinos and Watson (2005), and traced using Stereo Investigator 9.0; coordinates used for the amygdala were from bregma −2.6 to bregma −3.6; coordinates used for the hippocampus were from bregma −2.3 to bregma −6.3. The volume was calculated using the stereological probe called Cavalieri estimator. An overlay of a rectangular lattice with a grid size of 300 μm was placed over the tracings of the amygdala and the hippocampus, and each point marked was counted to estimate the volume. For each animal, the coefficient of error (CE) was calculated to ensure sufficient accuracy of the estimate (CE < 0.05).

Electrophysiologic Experiments. Thirty days after soman exposure, animals were decapitated after anesthesia with 3%–5% isoflurane. Coronal brain slices (400 μm thick) containing the amygdala (−2.64 to −3.36 from bregma) were cut using a vibratome (Leica VT 1200 S; Leica Microsystems, Buffalo Grove, IL) in ice-cold cutting solution consisting of (in millimolars): 115 sucrose, 70 N-methyl-d-glucamine, 1 KCl, 2 CaCl2, 4 MgCl2, 1.25 NaH2PO4, 30 NaHCO3. The slices were transferred to a holding chamber, at room temperature, in a bath solution containing (in millimolars): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 21 NaHCO3, 2 CaCl2, 1 MgCl2, and 11 glucose. Recording solution was the same as the holding bath solution. All solutions were saturated with 3%–5% CO2 to achieve a pH near 7.4. The recording chamber (0.7-ml capacity) had continuously flowing artificial cerebrospinal fluid (−6–8 ml/min) at temperature of 32 to 33°C. The osmolarity of this solution was adjusted to 325 mOsm with d-glucose.

Whole-cell recordings were obtained from neurons visualized under infrared light using Nomarski optics of an upright microscope (Axioskop 2; Zeiss, Thornwood, NY) through a 40× water immersion objective, equipped with a CCD-100 camera (Dage-MTI, Michigan City, IN). The patch electrodes had resistances of 3.5–4.5 MΩ when filled with the internal solution (in millimolars): 60 CsCH3SO3, 60 KCH3SO3, 5 KCl, 10 EGTA, 10 HEPES, 5 Mg-ATP, 0.3 Na3GTP (pH 7.2), 295 mOsm. Tight-seal (>1 GΩ) whole-cell recordings were obtained from the cell body of pyramidal neurons in the basolateral nucleus of the amygdala (BLA) region and identified based on their electrophysiologic properties (Sah et al., 2003; Park et al., 2007). Access resistance (15–24 MΩ) was regularly monitored during recordings, and cells were rejected if the resistance changed by more than 15% during the experiment. The Axopatch 200B amplifier (Axon Instruments, Foster City, CA) with a four-pole, low-pass Bessel filter, was used to amplify and filter (at 1 kHz) ionic currents and action potentials; the pClamp 10.5 software (Molecular Devices, Sunnyvale, CA) was used to digitally sample (up to 2 kHz) the signals, which were further analyzed using the Mini Analysis program (Synaptosoft Inc., Fort Lee, NJ) and Origin (OriginLab Corporation, Northampton, MA), as described previously (Fudoplichko et al., 2014). The charge transferred by synaptic currents was calculated using the Mini60 software (Synaptosoft Inc., Fort Lee, NJ). Electrical and chemical synapses were recruited with variable strength stimuli.

Statistical Analysis. Fisher’s exact test was used to compare the survival rate between the groups. Differences between groups in...
Results

Antilethality and Anticonvulsant Efficacy of the Treatments. Soman-exposed rats were randomly assigned into groups that received LY293558 as an anticonvulsant treatment (n = 40), DZP (n = 14), CRM (n = 65), or the combination of CRM and LY293558 (n = 40). Anticonvulsant treatments were administered 1 hour after soman injection. Survival rate for the LY293558-treated group was 87.5%, for the DZP-treated group 85.7% (no significant difference from the LY293558-treated group or the LY293558 + CRM group, \( P > 0.05 \)), for the CRM-treated group 64.6% (\( P < 0.05 \), significantly lower compared with the LY293558-treated group; \( P < 0.001 \), significantly lower compared with the LY293558 + CRM group; no significant difference from the DZP group, \( P = 0.21 \)), and for the LY293558 + CRM–treated group survival rate was 95%. All anticonvulsant treatments stopped SE (behavioral seizure score stage 2 or lower), except for CRM when administered alone. The latency to cessation of SE was 25 ± 3 minutes in the LY293558 group, 30 ± 5 minutes in the DZP group, and 13 ± 4 minutes in the LY293558 + CRM group (\( P < 0.05 \), in comparison with the LY293558 or the DZP groups). These results are summarized in Table 1; Fig. 1 shows the time course of the effect of the four anticonvulsant treatments on behavioral seizure scores.

Efficacy of the Anticonvulsant Treatments in Preventing Brain Damage. Neurodegeneration was present 1 month postexposure; it was more pronounced in the groups that were treated with DZP or CRM alone and absent in the group that was treated with LY293558 + CRM (Fig. 2). Thus, in the amygdala, neurodegeneration was mild in the LY293558-treated group (median = 2, IQR = 2–3; \( n = 14 \)), moderate in the DZP group (median = 3.5, IQR = 2.5–3.5; \( n = 12 \)), \( P = 0.06 \) compared with the LY293558 group), severe in the CRM group (median = 4, IQR = 3–4; \( n = 18 \), \( P < 0.05 \) compared with the LY293558 group), and absent in the LY293558 + CRM group (median = 0, IQR = 0–0; \( n = 18 \), \( P < 0.001 \), significantly lower compared with all other three groups). In the piriform cortex, neurodegeneration was minimal in the LY293558 and DZP groups (median = 1, IQR = 1–2), moderate in the CRM group (median = 3, IQR = 3–3; \( P < 0.05 \) compared with either the LY293558 or the DZP group), and absent in the LY293558 + CRM group (median = 0, IQR = 0–0; \( P < 0.01 \) compared with all other three groups). In the CA1 hippocampal area, neurodegeneration was mild in the LY293558-treated group (median = 2, IQR = 2–3), severe in the DZP group (median = 4, IQR = 3–4; \( P < 0.05 \) compared with the LY293558 group), moderate in the CRM group (median = 3.5, IQR = 3–4; \( P < 0.05 \) compared with the LY293558 group), and absent in the LY293558 + CRM group (median = 0, IQR = 0–0; \( P < 0.001 \) compared with all other three groups). In the CA3 hippocampal area, neurodegeneration was mild in the LY293558-treated group (median = 2, IQR = 2–3), severe in the DZP group (median = 4, IQR = 3–4; \( P < 0.05 \) compared with the LY293558 group), severe in the CRM group (median = 4, IQR = 3.25–4; \( P < 0.05 \) compared

---

**TABLE 1**

Survival rate and latency to cessation of SE in groups of soman-exposed rats treated with LY293558, DZP, CRM, or LY293558 + CRM at 1 hour after soman injection

<table>
<thead>
<tr>
<th></th>
<th>LY293558</th>
<th>DZP</th>
<th>CRM</th>
<th>LY293558+CRM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival rate</td>
<td>87.5% (35/40)</td>
<td>85.7% (12/14)</td>
<td>64.6% (42/65)**</td>
<td>95% (38/40) **</td>
</tr>
<tr>
<td>Cessation of SE</td>
<td>100% (40/40)</td>
<td>100% (14/14)</td>
<td>0 (0/65)</td>
<td>100% (40/40)</td>
</tr>
<tr>
<td>Latency to cessation of SE</td>
<td>25 ± 3 min</td>
<td>30 ± 5 min</td>
<td>–</td>
<td>13 ± 4 min *</td>
</tr>
</tbody>
</table>

* \( P < 0.05 \) compared with the LY293558 group; ** \( P < 0.001 \) compared with the LY293558 + CRM group; * \( P < 0.05 \) compared with either the LY293558 or the DZP groups.
with the LY293558 group), and absent in the LY293558 + CRM group (median = 0, IQR = 0–0; P < 0.001 compared with all other three groups). Finally, in the hilus of the hippocampus, neurodegeneration was absent in the LY293558-treated group (median = 0, IQR = 0–0), minimal in the DZP group (median = 2, IQR = 0.5–2), and absent in the LY293558 + CRM group (median = 0, IQR = 0–0); in both LY293550 alone and LY293558 + CRM groups, neurodegeneration in the hilus was significantly lower than that in the DZP and CRM groups (P < 0.05).

Since exposure to soman causes reduction in the amygdala and hippocampal volumes (Miller et al., 2015), we compared the efficacies of the anticonvulsant treatments in preventing this pathology. Thirty days after soman exposure, amygdala volume in the LY293558-treated rats (12.13 ± 0.2 mm³, n = 8) was not significantly different from that in the control (not exposed to the soman) group (12.48 ± 0.3 mm³, n = 8; P = 0.29; Fig. 3). Similarly, amygdala volume in the LY293558 + CRM–treated group (12.2 ± 0.3 mm³, n = 8) did not differ from that in the control group (P = 0.12). In contrast, amygdala volumes in the DZP group (10.2 ± 0.2 mm³, n = 8) and the CRM group (9.87 ± 0.5 mm³, n = 8) were significantly smaller compared with the control group (P < 0.01), the LY293558 group (P < 0.01), or the LY293558 + CRM group (P < 0.05; Fig. 3). Hippocampal volume in the LY293558–treated rats (61.85 ± 0.5 mm³, n = 8) was not significantly different from that in the control group (65.8 ± 0.8 mm³, n = 8;
Hippocampal volume in the LY293558 + CRM-treated group (63.18 ± 0.8 mm³, n = 8) also did not differ from that in the control group (P = 0.85). In contrast, hippocampal volumes in the DZP group (56.2 ± 0.7 mm³, n = 8) and the CRM group (50.48 ± 0.6 mm³, n = 8) were significantly smaller compared with the control group (P < 0.001), the LY293558 group (P < 0.05), or the LY293558 + CRM group (P < 0.01); in the CRM group, hippocampal volume was also significantly smaller than that in the DZP group (P < 0.05; Fig. 4).

Efficacy of the Anticonvulsant Treatments in Preventing Pathophysiologic Alterations in the Basolateral Amygdala. The amygdala is central to emotional behavior (Phelps and LeDoux, 2005), and its dysfunction is at the root of a host of neuropsychiatric disorders. Amygdala hyperexcitability is a characteristic feature of anxiety disorders (Anand and Shekhar, 2003; Etkin and Wager, 2007; Stein and Stein, 2008; Aroniadou-Anderjaska, 2015), and hyperexcitability in the basolateral nucleus of the amygdala (BLA) in particular is associated with increased anxiety-like behavior in animals (Sajdyk and Shekhar, 1997; Vazdarjanova et al., 2001; Shekhar et al., 2003; Wang et al., 2011; Aroniadou-Anderjaska et al., 2012; Pidoplichko et al., 2014). GABAergic control of the excitability of the BLA network appears to be particularly powerful (Rainnie, 1999; Chung and Moore, 2009; Ohshiro et al., 2011; Popescu and Paré, 2011), and we have shown previously that it is severely compromised after exposure to soman (Prager et al., 2014), along with an increase in anxiety-like behavior (Prager et al., 2015). Therefore, in the present study, we compared the efficacy of the anticonvulsant treatments in preventing the decrease in spontaneous inhibitory activity caused by soman exposure.

Most principal neurons in the BLA of control (not exposed to soman) rats (7 of 10 neurons) displayed rhythmic “bursts” of summated spontaneous induced pleuripotent stem cells (sIPSCs), as observed previously by others (Rainnie, 1999; Chung and Moore, 2009; Ohshiro et al., 2011; Popescu and Paré, 2011). Thirty days after soman exposure, bursts of
sIPSCs were also present in recordings from BLA principal cells in rats treated with LY293558 (four of eight neurons displayed sIPSC bursts) or LY293558 + CRM (7 of 13 neurons displayed sIPSC bursts). In contrast, sIPSC bursts were not present in BLA neurons recorded from DZP-treated rats (zero of eight neurons) or CRM-treated rats (zero of eight neurons). Representative examples are shown in Fig. 5A. To quantify these differences among groups, we calculated the total charge
transferred (the area delimited by the inhibitory current and the baseline), in pico Coulombs (pC), for a time window of 10 seconds; we included all recorded neurons in these comparisons, whether they generated rhythmic sIPSC bursts or displayed only conventional spontaneous inhibitory activity. The total charge transferred by sIPSCs in the LY293558 group (1940.31 ± 685.18 pC, n = 8) was not significantly different from that in the control group (2778.04 ± 708.11 pC, n = 10; P = 0.105; Fig. 5B). Similarly, the total charge transferred by sIPSCs in the LY293558 + CRM group (2347.12 ± 854.31, n = 13) did not differ from the control (P = 0.268). In contrast, the total charge transferred by inhibitory currents was significantly lower in both the DZP group (n = 8 neurons) and the CRM group (n = 8 neurons) compared with the control group. In the CRM group, it was also significantly lower compared with the LY293558 or the LY293558 + CRM groups. *P < 0.05; **P < 0.01.

Fig. 5. Efficacy of the anticonvulsant treatments in preventing the reduction of the background inhibitory activity in the basolateral amygdala (BLA): dramatic reduction of spontaneous IPSCs in the DZP- and CRM-treated groups. (A) Whole-cell recordings from principal BLA neurons (+30 mV holding potential) were obtained 30 days after soman exposure. In rats treated with DZP or CRM, spontaneous bursts of sumanted IPSCs were not present in any of the recorded neurons. The top “control” trace is representative from rats not exposed to soman. (B) Group data of the total charge transferred by spontaneous IPSCs (during a 10-second time window). The LY293558 group (n = 8 neurons) and LY293558 + CRM group (n = 13 neurons) did not differ from the control group (n = 10 neurons). In contrast, the total charge transferred by inhibitory currents was significantly lower in both the DZP group (n = 8 neurons) and the CRM group (n = 8 neurons) compared with the control group. In the CRM group, it was also significantly lower compared with the LY293558 or the LY293558 + CRM groups. *P < 0.05; **P < 0.01.

Efficacy of the Anticonvulsant Treatments in Preventing Increases in Anxiety-Like Behavior. Thirty days after exposure to soman, the anxiety level of rats in the different groups was examined in the open-field and the acoustic startle response tests. In the open-field test, the more anxious an animal is, the less time it spends in the center of the open field (Prut and Belzung, 2003). We found that the time spent in the center by the LY293558 group (88.4 ± 12.4 seconds or 10.6% ± 1.4% of the total movement time, n = 14) or the LY293558 + CRM group (118 ± 15 seconds or 13.7% ± 6.0% of the total movement time, n = 18) was not significantly different from the time spent in the center by the control (not exposed to soman) rats (102 ± 7.9 seconds or 12.9% ± 1.0% of the total movement time, n = 12; P = 0.180 for the LY293558 group and P = 0.676 for the LY293558 + CRM group). In contrast, the time spent in the center by the DZP group (54.8 ± 5.9 seconds or 6.8% ± 0.6% of the total movement time, n = 12) or the CRM group (56 ± 11.3 seconds or 6.7% ± 1.3% of the total movement time, n = 18) was significantly less compared with the control group (P < 0.01 for the DZP group and P < 0.001 for the CRM group), as well as with the LY293558 group (P < 0.05 for both the DZP and the CRM groups) and the LY293558 + CRM group (P < 0.001 for the DZP group and P = 0.001 for the CRM group; Fig. 6A). The distance traveled by the LY293558 group (2542 ± 166 cm), the DZP group (2478 ± 138 cm), the CRM group (2673 ± 198), and the LY293558 +
In the acoustic startle response test, the amplitude of the startle response to a 110-dB acoustic stimulus is a reflection of the anxiety level of the animal (Li et al., 2009). In response to the 110-dB acoustic stimulus, the amplitude of the startle in the LY293558 group (10.7 ± 1.58, n = 14) or the LY293558 + CRM group (11.89 ± 0.89, n = 18) was not significantly different from the startle amplitude in the control group (10.89 ± 1.48, n = 12; P = 0.93 for the LY293558 group and P = 0.74 for the LY293558 + CRM group). In contrast, the startle amplitude in the DZP group (17.33 ± 1.43, n = 12) or the CRM group (18.89 ± 0.9, n = 18) was significantly greater compared with the controls, the LY293558, or the LY293558 + CRM group (P < 0.05 for both the DZP and CRM groups; Fig. 6C, left panel). Similar results were obtained in response to the 120-dB acoustic stimulus. Thus, the amplitude of the startle in the LY293558 group (11.89 ± 1.22) or the LY293558 + CRM group (12.6 ± 1.12) was not significantly different from the startle amplitude in the control group (12.99 ± 1.12; P = 0.62 for the LY293558 group and P = 0.92 for the LY293558 + CRM group). In contrast, the startle amplitude in the DZP group (18.67 ± 0.99) or the CRM group (18.99 ± 0.85) was significantly greater compared with controls, the LY293558, or the LY293558 + CRM group (P < 0.01 for both the DZP and CRM groups; Fig. 6C, right panel).

**Discussion**

The present study showed that when LY293558, DZP, CRM, or LY293558 + CRM were administered 1 hour after acute exposure of P21 rats to a high dose of soman, LY293558, LY293558 + CRM, and DZP terminated the soman-induced SE, with the LY293558 + CRM combination acting with the fastest time course; CRM did not stop SE when administered alone. Evaluation of long-term effects, 30 days after soman exposure, showed that 1) LY293558 and LY293558 + CRM...
importantly, this compound does not protect against brain from the onset of SE lengthens (Shih and McDonough, 1999; de Araujo Furtado et al., 2010; McDonough et al., 2012; Todorovic et al., 2012; Apland et al., 2014) have shown that DZP can stop SE induced by nerve agents or other organophosphorus toxins and results in a high survival rate; however, not only the antiseizure efficacy of DZP is reduced as the latency of administration from the onset of SE lengthens (Shih and McDonough, 1999; McDonough et al., 2010; Todorovic et al., 2012), but, importantly, this compound does not protect against brain damage. DZP has been used in adult rat models of nerve agent exposure as a means to stop ongoing nerve agent–induced SE and then study neuropathology (e.g., de Araujo Furtado et al., 2010; Langston et al., 2012), suggesting that it is rather common knowledge that significant neuropathology will be found after DZP treatment. In these studies, SE is not allowed to continue for more than 1 hour before it is treated with DZP; yet, significant damage and/or long-term behavioral deficits can occur (de Araujo Furtado et al., 2010; Langston et al., 2012). In contrast, when LY293558 is administered after 1 hour of ongoing SE in soman-exposed adult rats, significant neuroprotection is achieved (Figueiredo et al., 2011b). In addition, when the efficacy of the specific GluK1R antagonist UBP302 was compared with that of DZP in soman-exposed adult rats, only UBP302 protected against neuropathology and behavioral deficits (Apland et al., 2014). Similarly to the results in these studies in adult rats, the present study in P21 rats showed that, in contrast to the efficacy displayed by LY293558, DZP provided little protection against neurodegeneration and did not prevent amygdala and hippocampal atrophy or the accompanying pathophysiologic and behavioral deficits. It should be noted that another benzodiazepine, midazolam, is being tested as a possible better alternative to DZP (Capacio et al., 2004; McDonough et al., 2009; Reddy and Reddy, 2015). The data reported so far show that midazolam can protect against nerve agent–induced brain damage in adult or young-adult rats if it is administered at the time of exposure (Chapman et al., 2015), at the onset of seizures (RamaRao et al., 2014), or after 5 minutes of seizure activity (Gilat et al., 2005); however, if it is given 1 hour after exposure, it does not prevent histologic damage, despite its antiseizure efficacy and beneficial effects on behavioral performance and inflammatory responses (Chapman et al., 2015). More studies are needed to understand the neuroprotective efficacy of midazolam administered at different time points after nerve agent exposure, and direct comparisons must be made with LY293558 under the same experimental conditions for two drugs.

**DZP Versus LY293558: Relating Mechanisms of Action to Neuroprotective Effects.** The low neuroprotective efficacy of DZP may be related to the transient nature of its seizure-suppressing effects. Shih and McDonough (1999) reported that 25% of the animals receiving 9 mg/kg DZP 5 minutes after the onset of soman-induced seizures had seizures recurring within the 6-hour monitoring period, whereas in rats receiving 10 mg/kg DZP at 1 hour after soman exposure, we found recurrence of seizures in all animals, resulting in a total duration of SE within 24 hours after exposure that does not differ from that in rats receiving no anticonvulant treatment (Apland et al., 2014). Although administration of DZP enhances GABAergic inhibition, thereby suppressing seizures, the function of the GABAergic system is weakened during seizure activity (Goodkin et al., 2005; Naylor et al., 2005; Deeb et al., 2012), and DZP itself may contribute to further desensitization and downregulation of GABA_A receptors (Usui-Oukari and Korpi, 2010; Vinkers and Olivier, 2012). Along with the rapid clearance rate of DZP (Ramsay et al., 1979), this may explain the recurrence of seizures when DZP is used as an anticonvulant treatment. Importantly, however, in a study where SE induced by exposure to paraxon was controlled by administration of DZP at 1, 3, and 5 hours after exposure to prevent recurrence of seizures, long-term cognitive and behavioral, depression-like deficits still developed (Deshpande et al., 2014b), suggesting that mechanisms other than seizure recurrence are involved in the inefficacy of DZP to protect against brain damage. Excessive increase in intracellular Ca^{2+} is largely responsible for seizure-induced neuronal degeneration and death (Holmes, 2002; Fujikawa, 2015), and prolonged elevations of intracellular Ca^{2+} have been found after acute organophosphate exposure despite treatment with DZP (Deshpande et al., 2014a). Apparently, enhancement of GABAergic inhibition by DZP does not adequately interfere with such Ca^{2+} elevations, which may in part explain the neuroprotective inefficacy of DZP. The insufficiency of targeting GABAergic inhibition to prevent brain damage may be particularly true in the young subjects, when GABA_A receptor–mediated synaptic activity can be depolarizing (Ben-Ari et al., 2012; Khazipov et al., 2015), thus exacerbating rather than suppressing network hyperexcitability.

In contrast to DZP, LY293558, administered after about 50–55 minutes of sustained soman-induced SE, not only suppressed seizures, but it also reduced neuronal degeneration and prevented amygdala and hippocampal atrophy, reduction of background inhibitory activity in the BLA, as well as the development of behavioral deficits. The antiseizure and neuroprotective efficacy of LY293558 can be attributed to the suppression of both AMPA receptor- and GluK1-containing kainate receptor activity. AMPA receptors, as primary mediators of glutamatergic transmission, are central to hyperexcitability, but they may also be directly involved in excitotoxicity by allowing Ca^{2+} influx (Kwak and Weiss, 2006; Yuan and Bellone, 2013). Their importance as targets for antiepileptic drugs has been emphasized previously (Rogawski, 2013; Serdyuk et al., 2014; Twele et al., 2015); however, the selectivity of LY293558 for the kainate receptors containing the GluK1 subunit is probably at least equally
important as selective GluK1 receptor antagonists with minimal antagonistic activity for AMPA receptors can alone block pilocarpine-induced seizures (Smolders et al., 2002), as well soman-induced SE and neuropathology (Apland et al., 2014). The mechanisms underlying the role of GluK1 kainate receptors in hyperexcitability and neuronal damage (Jae et al., 2009) involve not only postsynaptic mediation of glutamatergic transmission in principal neurons (Gryder and Rogawski, 2003) but also suppression of GABA release (Braga et al., 2003), facilitation of glutamate release (Aroniadou-Anderjaska et al., 2012), and permeability to Ca2+ (Rogawski et al., 2003; Joseph et al., 2011).

**Benefits of Combining CRM with LY293558.** When LY2935558 was coadministered with CRM, the latency to cessation of SE was significantly shorter than when LY2935558 was injected alone, and full neuroprotection was achieved as suggested by the absence of degenerating neurons in all brain regions examined. CRM is an antimuscarinic compound (a selective M1 antagonist; Hudkins et al., 1993); as such, it can block nerve agent-induced SE, but only if administered soon after exposure, when seizure activity is still significantly dependent on muscarinic receptor hyper-stimulation (Raveh et al., 2008). When CRM is administered alone at 1 hour after exposure of young adult rats to soman, it suppresses SE—allbeit with a slow time course—and exerts neuroprotection, but only at the relatively high dose of 100 mg/kg (Figueiredo et al., 2011a). In addition to its antimuscarinic effects, CRM may suppress hyperexcitability by other mechanisms (Annels et al., 1991; Church and Fletcher, 1995; Thurgur and Church, 1998), but its NMDA receptor antagonistic properties (Apland and Braim, 1990; Pontecorvo et al., 1991; Fletcher et al., 1995; Thurgur and Church, 1998; Figueiredo et al., 2011a) are likely to be primarily responsible for its neuroprotective efficacy (Raveh et al., 1999; Figueiredo et al., 2011a). In the P21 rats of the present study, a dose of 50 mg/kg did not suppress SE and did not prevent neuropathology when administered alone 1 hour after soman exposure. Extensive neurodegeneration was present in the CRM-treated group in all limbic structures studied, which probably explains the amygdala and hippocampal volume reduction. In addition, spontaneous inhibitory activity in the BLA was severely reduced in the CRM-treated group, and, consistent with the view that impaired inhibition in the BLA leads to anxiety (Shekhar et al., 2003; Truitt et al., 2009; Zhou et al., 2010), anxiety-like behavior was significantly increased (behavioral abnormalities after nerve agent exposure are reviewed in Aroniadou-Anderjaska et al., 2016). The synergistic neuroprotective effect seen when CRM was combined with LY2935558 can probably be attributed in large part to the NMDA receptor antagonistic properties of CRM, but other mechanisms may also be involved to a lesser extent. The LY2935558 + CRM combination treatment antagonizes AMPA, GluK1, and NMDA receptors, which, in contrast to the downregulation of GABA receptors (Goodkin et al., 2005; Naylor et al., 2005; Deeb et al., 2012), are all upregulated by seizure activity (Ullal et al., 2005; Li et al., 2010; Naylor et al., 2013; Rajasekaran et al., 2013).

In neonatal rats (P7), use of the benzodiazepine midazolam (Torolira et al., 2017). In the P21 rats of the present study, DZP did not worsen the brain damage induced by acute soman exposure, but it had little effect on neurodegeneration and did not prevent amygdalar and hippocampal volume reduction or increases in anxiety-like behavior. Therefore, in the event of mass exposure to nerve agents, if DZP is used to treat SE in children, lives may be saved, but the long-term morbidity can be expected to be high. In contrast, the combination of LY293558 + CRM not only can be expected to produce the highest survival rate but also to prevent long-term morbidity. CRM was approved by the FDA in 1973 as an over-the-counter antitussive for human use from the age of 2 years and older; FDA approval was withdrawn in 1984 because of the inefficacy of the drug as an antitussive, but not because of safety concerns. Clinical studies testing LY2935558 against seizures of various causes are certainly feasible and can be performed to obtain a dose range of efficacy and safety in humans. A combination therapy of LY2935558 with CRM, against nerve agent–induced SE, would allow reduction in the doses of both drugs, which would decrease the incidence of side effects and increase tolerability.

**Authorship Contributions**

Participated in research design: Braga, Aroniadou-Anderjaska, Apland.

Conducted experiments: Apland, Figueiredo, Pidoplichko.

Performed data analysis: Figueiredo, Pidoplichko, Rossetti, Apland, Braga, Aroniadou-Anderjaska.

Wrote or contributed to the writing of the manuscript: Aroniadou-Anderjaska, Apland, Braga, Figueiredo.

**References**


Address correspondence to: Dr. Maria F. M. Braga, Department of Anatomy, Physiology, and Genetics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814. E-mail: maria. braga@usuhs.edu.